EMCURE : APPROVES MERGER OF 2 WHOLLY OWNED SUBSIDIARIES INTO SELF

• Board approved composite scheme of amalgamation of Zuventus Healthcare and Emcutix Biopharmaceuticals with Emcure Pharmaceuticals • Both transferor companies are wholly owned subsidiaries of the company • No consideration payable and no new shares to be issued; entire share capital of transferors is held by Emcure • Zuventus FY26 turnover ₹1,040.58 Cr with networth ₹871.46 Cr; Emcutix turnover ₹29.37 Cr with networth negative ₹13.07 Cr • Emcure FY26 turnover ₹5,243.19 Cr and networth ₹3,710.60 Cr • Scheme subject to statutory and regulatory approvals including NCLT Mumbai Bench • Rationale: entity rationalization and operational efficiency; no change in Emcure's shareholding pattern

Emcure Pharmaceuticals Ltd

Open attachment

← Back to feed